Routine director sale tied to RSU vesting; no material signal for the stock. Monitor future insider activity for patterns, but this filing alone is inconsequential.
Price Chart
Executive Summary
Director Jay M. Moyes filed Form 144 indicating intent to sell 22,000 shares of Puma Biotechnology common stock, valued at approximately $159,720. The shares were acquired the prior day through restricted stock vesting as compensation. The proposed sale is routine and immaterial relative to the company's $368M market cap.
Key Facts
- Insider: Jay M. Moyes, a Director of Puma Biotechnology
- Proposed sale of 22,000 shares of common stock
- Estimated aggregate market value: $159,720 (~$7.26/share)
- Shares acquired on 2026-06-11 via restricted stock vesting (compensation)
- Sale intended on or about 2026-06-12
- Represents less than 0.05% of the company's market cap
Financial Impact
Negligible; proposed sale of ~$160k worth of shares represents a tiny fraction of the $368M market cap.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-004589 |
| Document: 0001959173-26-004589-index.html | 0001959173-26-004589 |
| Document: 0001959173-26-004589.txt | 0001959173-26-004589 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | SC 13D/A | $9.81 | awaiting T+20 | — | $10.92 (+11.31%) |
Sep 16, 2026 5w ago | Insider Cluster | $9.52 $10.52 | ▼ −10.50% | ▼ −9.30% | $10.92 (−14.71%) |
Jul 8, 2026 15w ago | Insider Cluster | $7.90 $8.12 | ▲ +2.78% | ▲ +0.54% | $10.92 (+38.23%) |
Jul 6, 2026 16w ago | 144 | $7.96 $7.69 | ▼ −3.39% | ▼ −4.72% | $10.92 (+37.19%) |
Jun 15, 2026 19w ago | Insider Cluster | $7.17 $8.28 | ▲ +15.48% | ▲ +15.28% | $10.92 (+52.30%) |
Jun 12, 2026 19w ago | 144 | $7.33 $8.00 | ▲ +9.14% | ▲ +7.36% | $10.92 (+48.98%) |
Feb 26, 2026 34w ago | 8-K | $5.70 $6.08 | ▲ +6.67% | ▲ +14.22% | $10.92 (+91.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers